Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar;76 Suppl 1(Suppl 1):S96-S100.
doi: 10.1016/j.ihj.2024.01.018. Epub 2024 Feb 8.

Management of dyslipidemia in special groups

Jayagopal P B  1 , Prafulla G Kerkar  2
Affiliations
Review

Management of dyslipidemia in special groups

Jayagopal P B et al. Indian Heart J. 2024 Mar.

Abstract

Dyslipidemia management in situations like pregnancy, in diseases like rheumatoid arthritis, human immunodeficiency virus (HIV) disease, chronic liver disease, and in the elderly are challenging scenarios. Pregnancy is a contraindication for many drugs. The interaction of various drugs used in HIV infection and rheumatoid arthritis makes it even more difficult to treat with conventional and approved drugs for dyslipidemia. Elderly and chronic renal failure patients often do not tolerate the drugs very well and the data of dyslipidemia management is very different. Lastly, COVID-19 is a unique scenario where clear information is yet to be provided. In this manuscript, the current understanding and available data on the treatment of dyslipidemia in these special situations are discussed.

Keywords: CKD dyslipidemia; HIV dyslipidemia; Pregnancy dyslipidemia.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Mach F., Baigent C., Alberico L., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188. - PubMed
    1. Preiss D., Campbell R.T., Murray H.M., et al. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J. 2015;36(24):1536–1546. - PMC - PubMed
    1. Al-Gobari M., Le H.H., Fall M., et al. No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: a meta-analysis of randomized controlled trials. PLoS One. 2017;12(2) - PMC - PubMed
    1. Feinstein M.J., Jhund P., Kang J., et al. Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. Eur J Heart Fail. 2015;17(4):434–441. - PubMed
    1. Bielecka-Dabrowa Agata, Bytyçi Ibadete, Von Haehling Stephan, et al. Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis. Lipids Health Disease. 2019;18:188. - PMC - PubMed